血清蛋白质质谱辅助孤立性肺结节的诊断

目的采用表面增强激光解析离子-飞行时间质谱（SELDI-TOF-MS）技术建立肺腺癌患者血清蛋白质质谱,筛选出相对特异标记物,探讨其用于辅助诊断孤立性肺结节的意义。方法肺腺癌患者71例,均经手术病理证实;正常志愿者71名,按照性别、年龄、吸烟史与71例肺腺癌患者配对。用WCX2芯片检测各血清标本,筛选肺腺癌相对特异性蛋白质峰。孤立性肺结节患者53例,其中28例接受手术治疗,根据术后病理诊断验证筛选出的肺腺癌相对特异性蛋白用于辅助诊断孤立性肺结节的意义。结果与正常志愿者比较,肺腺癌患者有5个显著高表达的相对特异性蛋白质,其相对分子质量分别为4047．79、4203．99、4959．81、5329．30和7760．12。28例接受手术治疗的孤立性肺结节患者中,有24例术后病理为肺腺癌,证实筛选出的5种肺腺癌相对特异性蛋白质具有较高的诊断价值。结论SELDI-TOF-MS技术是一种快速、简便易行且高通量的分析方法,能直接筛选出肺腺癌患者血清中相对特异的潜在标记物,将其用于辅助诊断孤立性肺结节可能具有较好的临床应用前景。

Serum proteomic patterns may assist the diagnosis of solitary pulmonary nodules

Objective To screen relatively specific biomarkers in serum from lung adenocarcinoma patients by surface-enhanced laser desorption and ionization time of flight mass spectrometry (SELDI-TOF-MS) , and to investigate the clinical value of SELDI-TOF-MS in differentiation of benign from malignant solitary pulmonary nodules ( SPN). Methods Serum samples from 71 lung adenocarcinoma patients and 71 healthy volunteers with matched gender, age and history of smoking were analyzed using WCX2 ProteinChip to screen potential biomarkers. 28 patients received surgical treatment among total 53 patients with SPN. The clinical value of SELDI-TOF-MS in differentiation of benign from malignant solitary pulmonary nodules was evaluated by pathological diagnosis. Results Five highly expressed potential biomarkers were identified with the relative molecular weights of 4047. 79 Da, 4203. 99 Da, 4959. 81 Da, 5329. 30 Da and 7760. 12 Da. The postoperative pathologic diagnosis was lung adenocarcinoma in 24 patients with SPN, validating the clinical value of the 5 potential biomarkers. Conclusion SELDI-TOF-MS technology is a quick, easy, convenient, and high-throughput analyzing method capable of screening several relatively specific potential biomarkers from the serum of lung adenocarcinoma patients and may have attractive clinic value in differentiation of solitary pulmonary nodules.